sábado, 14 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 19, 2026

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

View original at finance.yahoo.com
“lifted cash to $18.2B at year-end 2025 from $3.3B a year earlier.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SoFi Q1 2026 loan originations reached a record $12.18 billion, up 68% year-over-year

    60% confidence

  • Pfizer's non-COVID portfolio achieved 9% operational revenue growth

    60% confidence

  • Analyst target price for AT&T is $30.37

    60% confidence

  • AT&T's converged connectivity and growing free cash flow makes the dividend durable

    60% confidence

  • Pfizer faces a $1.5 billion revenue headwind in 2026 from loss of drug exclusivity and Most Favored Nation drug pricing pressure

    60% confidence

  • AT&T Q1 2026 adjusted EPS grew 11.8% year-over-year to $0.57

    60% confidence

  • SoFi Q1 2026 net income increased 134% year-over-year to $166.7 million

    60% confidence

  • Equity markets are trading at elevated multiples in May 2026

    60% confidence

  • AT&T legacy wireline revenue declined more than 20% in 2026

    60% confidence

  • AT&T grew its cash position from $3.3 billion at year-end 2024 to $18.2 billion at year-end 2025

    60% confidence

  • Analyst consensus target price for Pfizer is $29.19

    60% confidence

  • Analyst target price for SoFi Technologies is $21.10

    60% confidence

Data points we hold from this source

AT&T Inc. · debt173.99 USD
AT&T Inc. · analyst target price30.37 USD
AT&T Inc. · forward pe11 multiple
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look — Source | Via News | pt.VIA.NEWS